Replimune Group Inc

NASDAQ REPL

Data sourced from

and

Download Data

Replimune Group Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2024: 0.23

Replimune Group Inc Total Liabilities to Total Assets Ratio is 0.23 for the quarter ending March 31, 2024, a 64.40% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition.

Replimune Group Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2023 was 0.14, a 30.34% change year over year.
Replimune Group Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2022 was 0.11, a 32.60% change year over year.
Replimune Group Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2021 was 0.08, a -62.04% change year over year.
Replimune Group Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2020 was 0.22, a 101.65% change year over year.

NASDAQ: REPL

Replimune Group Inc

CEO	Mr. Philip Astley-Sparke FSA
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees	331
Sector	Healthcare
Industry	Biotechnology

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends